close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

26.45 -0.36 (-1.36%)
Streaming Delayed Price Updated: 2:30 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
News headline image
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial ↗
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency 
Via Benzinga
News headline image
Beam Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics ↗
 
Via Benzinga
News headline image
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
News headline image
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating ↗
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
News headline image
3 Gene Editing Stocks with Potential to Transform Medicine ↗
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
Via InvestorPlace
News headline image
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
News headline image
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
News headline image
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
News headline image
Why Is Conn’s (CONN) Stock Down 36% Today? ↗
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
News headline image
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 ↗
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock. 
Via InvestorPlace
News headline image
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
3 Gene Editing Stocks Shaping the Future of Medicine ↗
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
Via InvestorPlace
News headline image
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast ↗
 
Via Benzinga
News headline image
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
News headline image
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
News headline image
3 Stocks With the Potential to 10X Your Money ↗
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. 
Via InvestorPlace
News headline image
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
News headline image
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 ↗
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. ↗
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today